<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409643</url>
  </required_header>
  <id_info>
    <org_study_id>CVAA489A2307</org_study_id>
    <nct_id>NCT00409643</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This trial will compare valsartan and amlodipine combination therapies to valsartan and&#xD;
      amlodipine monotherapy,and placebo for treating patients with hypertension&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough (endpoint-Week 8).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Visit 2) in mean sitting systolic blood pressure at trough (endpoint-Wk 8)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Visit 2) in standing diastolic and systolic blood pressure at trough(endpoint-Wk 8)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitting and standing pulse</measure>
  </secondary_outcome>
  <enrollment type="Actual">1259</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan+amlodipine combination</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients 18 years and older.&#xD;
&#xD;
          -  Male or female patients are eligible. Female patients must be either post-menopausal&#xD;
             for one year or surgically sterile, or using effective contraceptive methods such as&#xD;
             barrier method with spermicide or an intra-uterine device. Hormonal contraceptive use&#xD;
             is disallowed.&#xD;
&#xD;
          -  Patients with essential diastolic hypertension measured by calibrated standard aneroid&#xD;
             or mercury (preferable) sphygmomanometer. Patients must have a MSDBP &gt; 90 mmHg and &lt;&#xD;
             110 mmHg at Visit 1 (week -4 to -2), and a MSDBP &gt; 95 mmHg and &lt; 110 mmHg at Visit 2&#xD;
             (week 0).&#xD;
&#xD;
          -  Patients must have an absolute difference of &gt; 10 mmHg in their average sitting&#xD;
             diastolic blood pressure between Visits 1 and 2.&#xD;
&#xD;
          -  Patients who are eligible and able to participate in the study, and who consent to do&#xD;
             so after the purpose and nature of the investigation has been clearly explained to&#xD;
             them (written informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hypertension (MSDBP 110 mmHg and/or MSSBP 180 mmHg) at anytime.&#xD;
&#xD;
          -  Inability to discontinue all prior antihypertensive medications safely for a period of&#xD;
             14 weeks.&#xD;
&#xD;
          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.&#xD;
&#xD;
          -  History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to&#xD;
             Visit 0 (week -6 to -4).&#xD;
&#xD;
          -  Transient ischemic cerebral attack during the last 12 months prior to Visit 0 (week -6&#xD;
             to -4).&#xD;
&#xD;
          -  Evidence of a secondary form of hypertension, such as coarctation of the aorta,&#xD;
             hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing Disease,&#xD;
             pheochromocytoma, polycystic kidney disease etc.&#xD;
&#xD;
          -  Type 1 diabetes mellitus.&#xD;
&#xD;
          -  Type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated&#xD;
             hemoglobin (HbA1c) &gt;8% at Visit 1 (week -4 to -2).&#xD;
&#xD;
          -  Administration of any agent indicated for the treatment of hypertension within a&#xD;
             minimum 4 weeks prior to randomization into the study (Visit 2, week 0), with the&#xD;
             permitted exception of those anti-hypertensive medications requiring tapering down&#xD;
             commencing at Visit 0 (week -6 to -4).&#xD;
&#xD;
          -  Known or suspected contraindications, including history of allergy to angiotensin&#xD;
             receptor blockers or calcium channel blockers.&#xD;
&#xD;
          -  Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites in Germany</name>
      <address>
        <city>Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HYPERTENSION, VALSARTAN, AMLODIPINE, high blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

